Blood eosinophils as predictor of outcomes in patients hospitalized for COPD exacerbations: a prospective observational study

References

• Attaway, A.H, et al., 2021. Muscle loss contributes to higher morbidity and mortality in COPD: An analysis of national trends. Respirology, 26(1), 62–71.
   PubMed Web of Science ®Google Scholar
• Bafadhel, M., et al., 2011. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. American journal of respiratory and critical care medicine, 184 (6), 662–671.
   PubMed Web of Science ®Google Scholar
• Bafadhel, M., et al., 2012. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. American journal of respiratory and critical care medicine, 186 (1), 48–55.
   PubMed Web of Science ®Google Scholar
• Bafadhel, M., et al., 2014. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. The European respiratory journal, 44 (3), 789–791.
   PubMed Web of Science ®Google Scholar
• Bafadhel, M., et al., 2016. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest, 150 (2), 320–328.
   PubMed Web of Science ®Google Scholar
• Bafadhel, M., Pavord, I.D., and Russell, R.E.K., 2017. Eosinophils in COPD: just another biomarker? The lancet. Respiratory medicine, 5 (9), 747–759.
   PubMed Web of Science ®Google Scholar
• Bafadhel, M., et al., 2020. Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis. Respiratory research, 21 (1), 17.
   PubMed Web of Science ®Google Scholar
• Casanova, C., et al., 2017. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. European respiratory journal, 50 (5), 1701162.
   PubMed Web of Science ®Google Scholar
• Chang, C., et al., 2015. Bacterial infection, airway and systemic inflammation and clinical outcomes before and after treatment of AECOPD, a longitudinal and cross-sectional study. COPD, 12 (1), 19–30.
   PubMedGoogle Scholar
• Duman, D., et al., 2015. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. International journal of chronic obstructive pulmonary disease, 10, 2469–2478.
   PubMed Web of Science ®Google Scholar
• Echevarria, C., et al., 2018. Home treatment of COPD exacerbation selected by DECAF score: a non-inferiority, randomised controlled trial and economic evaluation. Thorax, 73 (8), 713–722.
   PubMed Web of Science ®Google Scholar
• Ho, J., et al., 2017. Eosinophilia and clinical outcome of chronic obstructive pulmonary disease: a meta-analysis. Scientific reports, 7 (1), 13451.
   PubMed Web of Science ®Google Scholar
• Holland, M., et al., 2010. Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease. Respirology, 15 (1), 165–167.
   PubMed Web of Science ®Google Scholar
• Hurst, J.R., et al., Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators, 2010. Susceptibility to exacerbation in chronic obstructive pulmonary disease. The New England journal of medicine, 363 (12), 1128–1138.
   PubMed Web of Science ®Google Scholar
• Ko, F.W.S., et al., 2020. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. Respirology (Carlton, Vic.), 25 (3), 259–266.
   PubMed Web of Science ®Google Scholar
• Kreindler, J.L., et al., 2016. Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. BMJ open respiratory research, 3 (1), e000151.
   PubMed Web of Science ®Google Scholar
• MacDonald, M.I., et al., 2019. Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD. Chest, 156 (1), 92–100.
   PubMed Web of Science ®Google Scholar
• Meijer, R.J., et al., 1999. Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma. Thorax, 54 (10), 894–899.
   PubMed Web of Science ®Google Scholar
• Negewo, N.A., et al., 2016. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. International journal of chronic obstructive pulmonary disease, 11, 1495–1504.
   PubMed Web of Science ®Google Scholar
• Oshagbemi, O.A., et al., 2017. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. American journal of respiratory and critical care medicine, 195 (10), 1402–1404.
   PubMed Web of Science ®Google Scholar
• Papaioannou, A.I., et al., 2017. Emphysematous phenotype is characterized by low blood eosinophils: a cross-sectional study. COPD, 14 (6), 635–640.
   Google Scholar
• Pascoe, S., et al., 2019. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. The lancet. Respiratory medicine, 7 (9), 745–756.
   PubMed Web of Science ®Google Scholar
• Pavord, I.D., et al., 2017. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. The New England journal of medicine, 377 (17), 1613–1629.
   PubMed Web of Science ®Google Scholar
• Pavord, I.D., et al., 2016. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. The lancet. Respiratory medicine, 4 (9), 731–741.
   PubMed Web of Science ®Google Scholar
• Peng, C., et al., 2013. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. The American journal of the medical sciences, 345 (3), 190–194.
   PubMed Web of Science ®Google Scholar
• Prins, H.J., et al., 2017. Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD. Respiratory medicine, 131, 118–124.
   PubMed Web of Science ®Google Scholar
• Rehman, A.U., et al., 2020. The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. The European journal of health economics: HEPAC: health economics in prevention and care, 21 (2), 181–194.
   PubMed Web of Science ®Google Scholar
• Schumann, D.M., et al., 2019. Stability of the blood eosinophilic phenotype in stable and exacerbated COPD. Chest, 156 (3), 456–465.
   PubMed Web of Science ®Google Scholar
• Seemungal, T.A., et al., 1998. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 157 (5), 1418–1422.
   PubMed Web of Science ®Google Scholar
• Shin, S.H., et al., KOLD Study Group, 2018. Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease. Respiratory research, 19 (1), 134.
   PubMedGoogle Scholar
• Singh, D., et al., 2019. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD Science Committee Report 2019. European respiratory journal, 53 (5), 1900164.
   PubMed Web of Science ®Google Scholar
• Singh, D., et al., ECLIPSE investigators, 2014. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. The European respiratory journal, 44 (6), 1697–1700.
   PubMed Web of Science ®Google Scholar
• Suissa, S., Dell'Aniello, S., and Ernst, P., 2012. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax, 67 (11), 957–963.
   PubMed Web of Science ®Google Scholar
• Turato, G., et al., 2018. Blood eosinophilia neither reflects tissue eosinophils nor worsens clinical outcomes in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 197 (9), 1216–1219.
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh, S., et al., 2016. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. American journal of respiratory and critical care medicine, 193 (9), 965–974.
   PubMed Web of Science ®Google Scholar
• Vogelmeier, C.F., et al., 2019. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respiratory research, 20 (1), 178.
   PubMed Web of Science ®Google Scholar
• Wu, H.-X., Zhuo, K.-Q., and Cheng, D.-Y., 2019. Peripheral blood eosinophil as a biomarker in outcomes of acute exacerbation of chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease, 14, 3003–3015.
   PubMed Web of Science ®Google Scholar
• Yun, J.H., et al., COPDGene and ECLIPSE Investigators, 2018. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. The journal of allergy and clinical immunology, 141 (6), 2037–2047.e10.
   PubMed Web of Science ®Google Scholar